A. Milicic

The adjuvant access problem: barriers to broader vaccine development

Vaccine development increasingly depends on adjuvants, particularly for antigen-based platforms that require immune enhancement to achieve protective efficacy. Vaccine adjuvants do more than boosting humoral responses; they can also enable antigen dose-sparing and promote Th1-skewed cellular immunity needed for intrace...